Develop cancer treatments and immunotherapeutics with models covering various cancer types with syngeneic, CDX, PDX, and custom models.
Leverage our aged macular degeneration models and our custom models to develop novel ophthalmology treatments.
Study metabolic and fatty liver disease with chronic and acute nonalcoholic steatohepatitis (NASH) models.
Other In Vivo Models
We have experience working with a variety of in vivo pharmacology models, genetic models, surgical models, and models based on drug mechanisms of action. If we don’t have what you’re looking for, we’d love to develop a custom in vivo model for you.
Analyze the impact of treatments over a long period of time by leveraging our expertise in handling aged and senescent models.
Ready to advance your preclinical research with in vivo models?
Gain the in vivo pharmacology information you need to move your therapeutic forward.
We’re different from other CROs, which tends to lead to a lot of questions. Here are the answers to some common ones related to our in vivo disease models.
What in vivo models do you work with? Can you build a custom model?
Because we are comfortable working with almost any model, we don’t like providing a catalog of models. Instead, send us a message so we can explore the best model for you. If we don’t have what you need, we can build it for you.
What kind of drug modalities can you handle?
We can handle all drug modalities and also cellular therapies.
What type of routes of administrations can you handle?
We have capabilities to handle all the usual routes of administration , SC, IV, IP, IM, and can also perform retino-orbital and tail vein injections.
What animal species do you work with?
Most of our efficacy studies are done in rodents (rats and mice). However, we have the capabilities and licenses to work on larger species such as rabbits, canines and mini-pigs.
How soon can you start a study once a contract is in place?
This would depend on the queue at that time but we typically are able to start studies within 4-5 weeks for most studies.
Recombinant Manganese Peroxidase Reduces A2E Burden in Age-Related and Stargardt's Macular Degeneration Models
Coevolution of the Ess1-CTD axis in polar fungi suggests a role for phase separation in cold tolerance